Over 40 European industry organizations released a joint statement arguing that Europe needs biomanufacturing legislation, and it needs it soon.
The statement warns that Europe is the only major global region without a dedicated biomanufacturing initiative, even though its bioeconomy and biopharma sectors contributed over €3 trillion in 2022-23.
The problem, according to the signatories, is regulatory fragmentation. Different rules across member states create bottlenecks that slow down production scale-up and make it harder for innovations to reach the market.
Meanwhile, competitors are moving fast. China’s five-year plan puts biomanufacturing alongside 6G and quantum computing, with ambitious targets for pharmaceuticals, food, and industrial chemicals. The U.S. and India have their own biomanufacturing priorities.
The EU Biotech Act I focused mainly on health applications. Industry groups say what’s needed now is broader legislation that covers all sectors and helps companies move from research to commercial production.
The proposed Biotech Act II would create a framework for coordination, market entry, and industrial scale-up. The goal is to unlock private investment and turn Europe’s scientific research into actual industrial output.
Groups signing the statement include national biotech associations from Germany, Denmark, Sweden, and Switzerland, plus European trade bodies representing food fermentation, biosolutions, and specialty ingredients.
The European Commission is expected to introduce the legislation later this year. Whether it will address industry concerns remains to be seen.
The post European biotech industry urges action on biomanufacturing act appeared first on World Bio Market Insights.
- Source: https://worldbiomarketinsights.com/european-biotech-industry-urges-action-on-biomanufacturing-act/
